Diligence memo · auto-generated · as of July 2, 2026
Sherlock Biosciences, Inc.
Sherlock Biosciences, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Sherlock Biosciences, Inc. operates in Biotech / Pharma, based in BRIGHTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sherlock Biosciences, Inc. has raised $113M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $80M on 2022-02-28.
Most recent recorded round closed around 2022-02-28.
Valuation (modeled)modeled
Provath models Sherlock Biosciences, Inc. at approximately $1.7B (range $254M–$3.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.29× the median modeled value of Series C Biotech / Pharma companies in 2022–2024 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 35 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Pacific Biosciences Of California, Inc., Sudo Biosciences, Inc., Elephas Biosciences Corp, NOLA PharmaHoldings, LLC, Belenos Biosciences, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.